Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 137 clinical trials
None
Prebiotics in the Prevention of Necrotizing Enterocolitis

Necrotizing enterocolitis (NEC) is the most common gastrointestinal catastrophe affecting 10-15% of premature neonates of <1500 gm. NEC is a disease of the immature intestine

prebiotics
premature birth
sepsis
  • 0 views
  • 07 Nov, 2020
  • 1 location
None
Primary Anastomosis Versus Enterostomy in the Surgical Treatment of Necrotising Enterocolitis

Necrotizing enterocolitis (NEC) is a devastating disease that affects the intestine of premature infants and is the most common surgical emergency in newborns. It is estimated that up to 10% of

  • 0 views
  • 08 Oct, 2021
None
Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae

The purpose of this study is to determine whether the NEC device can effectively occlude the intracranial aneurysm or the carotid/vertebrobasilar fistula and maintain parent vessel

ruptured aneurysm
saccular aneurysm
  • 18 views
  • 08 Nov, 2020
  • 2 locations
None
Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis

348,900 every year. 3. Necrotizing enterocolitis is one of the fatal complications (NEC) 3, 4. Preterm newborns weighing 1500 grams or less are considered high risk. 5-6. Melatonin is one chemical

  • 0 views
  • 31 Oct, 2021
  • 1 location
None
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.

  • 0 views
  • 08 Sep, 2021
  • 2 locations
None
Erythropoietin in Premature Infants to Prevent Encephalopathy

The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in preterm infants improves neurodevelopmental outcome at 18 months corrected age. This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 312 patients.

  • 0 views
  • 15 Mar, 2021
  • 1 location
None
Treatment of ppROM With Erythromycin vs. Azithromycin Trial

Preterm premature rupture of membranes (PPROM) complicates 4% of pregnancies annually. This pregnancy complication is a major contributor to preterm births and results in neonatal morbidity and mortality. The current standard of care for PPROM subjects between the gestational age of 24 weeks and 0 days and 33 weeks and …

  • 3 views
  • 27 Jan, 2021
  • 4 locations
None
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody

metastatic merkel cell carcinoma
avelumab
  • 0 views
  • 31 Oct, 2021
  • 46 locations
None
NICU Antibiotics and Outcomes Trial

-onset sepsis (LOS), necrotizing enterocolitis (NEC), or death during the index hospitalization. Secondary safety outcomes will include total antibiotic days, days to full enteral feedings, and common

  • 0 views
  • 14 Jun, 2021
  • 13 locations
None
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously …

cavity
cancer
programmed cell death 1 ligand 1
renal function
dental caries
  • 1828 views
  • 22 Mar, 2021
  • 47 locations